The transactions highlighted below are representative of Greenhill engagements. In addition, the Firm has completed many engagements that were not publicly-disclosed.
Recent Transactions
Sort By

Perseus Books LLC

Advised Perseus Books LLC, a leading independent publishing company, on the sale of its client services business to Ingram Content Group Inc.

Perseus Books LLC

Advised Perseus Books LLC, a leading independent publishing company, on the sale of its publishing business to Hachette Book Group, Inc.

Recepta Biopharma

Advised Recepta Biopharma on a capital raise

Specialized Anodized Extrusion Holding Switzerland AG (Spandex)

Advised Gilde Buy Out Partners on the sale of Spandex, a specialized B2B distributor of graphic media and equipment to the signage and visual communications industry, to Chequers Capital

Allied Healthcare

Advised Saga plc on the disposal of Allied Healthcare, the leading local authority-funded domiciliary care business in the UK, to AURELIUS Investments

Aesynt, Inc.

Advised Omnicell, Inc., a leading supplier to health systems of automation solutions and business analytics software for medication and supply management, on the acquisition of Aesynt, Inc., a provider of integrated pharmacy automation solutions for hospitals and health systems

Victorian Thoroughbred Racing Media Rights

Advised Tabcorp Holdings Limited (“Tabcorp”), a leading diversified Australian entertainment group with wagering, gaming, racing media and Keno operations, on reaching agreement on a long-term deal for domestic broadcast, digital and international media rights for Victorian thoroughbred racing content

Allergan Generics

Advised Teva Pharmaceutical Industries Ltd., a leading global pharmaceutical company, on the acquisition of Allergan plc’s Generics business

Altegra Health, Inc.

Advised Emdeon, a leading healthcare information technology company, on the acquisition of Altegra Health, a national provider of technology and intervention platforms for value-based healthcare

Aralez Pharmaceuticals Inc.

Advised QLT Inc. on its strategic equity investment in Aralez Pharmaceuticals Inc., a newly formed global specialty pharmaceutical company resulting from the business combination of POZEN Inc. and Tribute Pharmaceuticals Canada Inc., and the special distribution of the Aralez shares to QLT shareholders.

Portfolio of GlaxoSmithKline plc consumer and OTC brands

Advised GlaxoSmithKline plc, a leading British pharmaceutical company, on the disposal of a portfolio of consumer and OTC brands to Omega Pharma NV, a subsidiary of Perrigo Company plc

Telecity Group plc

Advised Telecity Group plc, Europe’s leading provider of premium carrier-neutral data centres, on a recommended cash and share offer from Equinix, Inc. a leading US provider of colocation data centre services globally

Scholastic Corporation’s Educational Technology and Services business

Advised Scholastic Corporation, a children’s publishing and education company, on the sale of its Educational Technology and Services business to Houghton Mifflin Harcourt Company, an educational and trade publisher

Refinancing of syndicated bank debt facilities

Advised Primary Health Care on the refinancing of its A$1.25 billion syndicated bank debt facilities

Wireline assets of Verizon Communications in California, Florida and Texas

Advised the Board of Directors of Frontier in connection with its acquisition of wireline assets from Verizon in California, Florida and Texas

NSW Thoroughbred Racing Media Rights

Advised Tabcorp Holdings Limited (“Tabcorp”), a leading diversified Australian entertainment group with wagering, gaming, racing media and Keno operations, on reaching agreement on a long-term deal for domestic broadcast, digital and international media rights for NSW thoroughbred racing content, and a contemporaneous Pay TV deal with Foxtel

Chandler Macleod Group Limited

Advised Recruit Holdings Co.,Ltd, the leading global staffing services company in Japan, on the acquisition of Chandler Macleod Group Limited, a major general recruitment company

Peoplebank Holdings PTY LTD

Advised Recruit Holdings Co.,Ltd, the leading global staffing services company in Japan, on the acquisition of Peoplebank Holdings PTY LTD, Australasia’s leading IT&T recruitment company

Tipness Limited

Advised Nippon Television Holdings, a media and content company engaged in production and broadcasting primarily in Japan, on the acquisition of Tipness Limited, the fourth largest fitness club company in Japan, from Suntory Holdings and Marubeni Corporation

MannKind Corporation

Advised MannKind, a biopharmaceutical company focused on the development of therapeutic products for patients with diabetes, on a collaboration with Sanofi, comprising licensing, supply and loan facility agreements with respect to licensing the Company’s lead product AFREZZA. MannKind will receive up to $925 million in upfront and milestone payments plus 35% of future profits.

Siemens Health Services

Advised Cerner Corporation, a leader in healthcare information services, on the acquisition of the assets of Siemens Aktiengesellschaft’s healthcare information technology business unit, Siemens Health Services, for $1.3 billion in cash.

Gannett Co., Inc.

Advised Gannett Co., Inc. a media and marketing solutions company, on the spin-off of its Publishing business and the creation of two separate media companies: one focused on television broadcasting and digital marketing and one focused on newspapers.

Cars.com

Advised Gannett Co., Inc. a media and marketing solutions company, on its acquisition of Cars.com (part of Classified Ventures, LLC), a provider of online auto advertising solutions and consumer content.

Global Trade Information Services, Inc.

Advised Global Trade Information Services, the world’s leading supplier of international merchandise trade data, on the sale of the company to IHS.

Clinuvel Pharmaceuticals Limited

Advised Clinuvel, a biopharmaceutical company focused on developing drugs for the treatment of a range of severe skin disorders, in response to an unsolicited proposal to acquire the business from Retrophin, a pharmaceutical company focused on the development, acquisition and commercialization of drugs for the treatment of serious, catastrophic or rare diseases